



Invesco India Pharma and Healthcare Fund

NFO Period: 18 Aug - 1 Sep, 2026

A smart move towards wealthcare.




SEBI Registered Name - Invesco Mutual Fund | SEBI Registration Number - MF/052/06/01


Invesco India Pharma and Healthcare Fund
(An open ended equity scheme investing in Pharma, Healthcare and allied sectors)

This product is suitable for investors who are seeking*:

- Capital appreciation over long term
- Investments predominantly in equity and equity-related instruments of pharma, healthcare and allied companies



As per AMFI
Tier 1
Benchmark
i.e. **BSE
Healthcare
TRI**



***Investors should consult their financial advisers if in doubt about whether the product is suitable for them.**

Note: The above product labelling assigned during the New Fund Offer (NFO) is based on internal assessment of the scheme characteristics or model portfolio and the same may vary post NFO when the actual investments are made.

India's healthcare sector has evolved well beyond its traditional pharmaceutical strengths to become a globally significant healthcare ecosystem. Alongside its position as one of the world's largest producers of pharmaceuticals, generic medicines, vaccines, and its extensive network of USFDA-approved manufacturing facilities, the sector is witnessing rapid growth across healthcare delivery, diagnostics, biotechnology, insurance, and digital health infrastructure. Together, these segments are enhancing India's competitiveness and strengthening its status as a leading global healthcare hub.

Source: Boston Consulting Group, Pharmaceuticals Export Promotion Council of India Annual Report 2024-25, Crisil Intelligence, Press Information Bureau – Government of India.

India's healthcare ecosystem: At a glance



Talent depth

~30–35% of global STEM graduates (~2.5-2.6 million annually)

~5 lakh pharmacy graduates annually (largest globally)

Extensive education base: **1,300+** biotech **4,900+** pharmacy colleges



Cost advantage

65–70% lower FTE costs vs US (~45–60% vs Europe)

~75% lower R&D cost and ~55% lower manufacturing cost vs US

50–60% cheaper clinical trials vs US



Patient scale and diversity

1.4 billion population with unmatched genetic diversity

Significant disease burden: ~40% of global cancer burden for specific cancers like oral cancer
~25% of global TB patients
15-20% of global diabetes patients



Digital infrastructure and scalability

Implemented and scaled the world's largest public healthcare scheme, AB-PMJAY, covering **55-60 crore** individuals.

~92 crore ABHA IDs (~60% population)

~5.3 lakh health facilities on ABDM



Size & scale

3rd largest in the world by volume and **11th** largest by value in the global pharmaceuticals market

Indian pharma accounts for ~20% of global generic medicines

873 USFDA approved plants in India out of ~4,250 total

STEM: Science, Technology, Engineering, Mathematics. FTE: Full-time Equivalent. AB-PMJAY: Ayushman Bharat Pradhan Mantri Jan Arogya Yojana. ABHA: Ayushman Bharat Health Account. ABDM: Ayushman Bharat Digital Mission. R&D: Research and Development. USFDA: US Food and Drug Administration.

Source: Boston Consulting Group. Press Information Bureau – Government of India. Data as on July 15, 2026.

Why invest in pharma and healthcare sector?



Long term structural growth driven by improving healthcare access, rising affordability, ageing populations, and growing disease burden.



Resilient and defensive, supported by non-discretionary demand, delivering stable growth across economic and market cycles.




Multiple growth engines across pharma, hospitals, diagnostics, CDMO, medical devices, and health insurance, offering diversified exposure.



Distinct growth catalysts across healthcare segments underpinning broad-based and sustainable growth across the healthcare value chain.

Diverse and expanding healthcare opportunities

India Healthcare Market Revenue Mix



CDMO: Contract Development and Manufacturing Organization. R&D: Research and Development. E: Estimate.
Source: Crisil Intelligence, F&S, PIB, Invesco Asset Management (India). Data as on November 30, 2025.
Disclaimer: The statements contained herein may include statements of future expectations and other forward looking statements that are based on prevailing market conditions / various other factors and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements.

Each healthcare segment is driven by unique growth catalysts, from rising chronic diseases & healthcare penetration to outsourcing, capacity expansion, preventive care, and insurance adoption. **This diversified demand base creates a resilient, long-term growth opportunity across the healthcare value chain.**


Segment	Growth Driver	Investment Opportunity / Rationale
Domestic Pharma	Chronic therapies	Sustained volume growth from rising lifestyle disease burden
	Premiumization	Higher realizations through complex and specialty brands
CDMO / CRO / API	China+1 opportunity	Global supply chain diversification boosts order inflows
	Outsourcing tailwind	Increased pharma outsourcing supports long-term demand visibility
Hospitals	Capacity expansion	Revenue growth driven by bed additions and network expansion
	Rising occupancy	Operating leverage improves profitability as utilization increases
Diagnostics	Chronic diseases	Rising incidence of lifestyle disease burden
	Preventive healthcare	Growing health awareness drives higher testing volumes
Insurance	Rising healthcare affordability	Expanding insurance penetration broadens addressable market

CDMO: Contract Development and Manufacturing Organization. CRO: Contract Research Organization. API: Active Pharmaceutical Ingredient.
Source: Invesco Asset Management (India).
Disclaimer: The list of segments mentioned above is not an exhaustive list and there could be other segments as well. It should not be construed as recommendation, advice to buy, sell or transact in any manner in these segments and neither should it be considered as Research Report from Invesco Asset Management (India) Private Limited ('IAMI') and/or Invesco Mutual Fund ('IMF'). It should neither be construed as an investment strategy nor an investment advice to any party. The Scheme may or may not take any positions in these segments.

Presenting Invesco India Pharma and Healthcare Fund

The scheme aims to generate long term capital appreciation by investing predominantly in equity and equity related securities of the companies in Pharmaceuticals, Healthcare and allied sectors.


Why invest?



Disclaimer: The current portfolio positioning is based on our current views and market conditions and are subject to change from time to time.

Long Compounding Runway

BSE Healthcare has delivered noteworthy performance – BSE Healthcare TRI vs Nifty 50 TRI



CAGR: Compounded Annualised Growth Rate. BSE HC: BSE Healthcare. Standard Deviation is a measure of Volatility. Beta measures how much a stock's price moves compared to the overall market.

Past performance may or may not be sustained in future

Source: MFIE. Data as on July 31, 2026. The values have been rebased to 10,000 at the beginning of the period. Volatility (Risk) and Beta is calculated on daily rolling returns.

Disclaimer: The above chart shows the performance of BSE Healthcare TRI (thematic index) and Nifty 50 TRI (broader index) for the past 20 years i.e. from July 31, 2006 to July 31, 2026 and should not be construed as performance of the Scheme. The above analysis is for illustration purpose only. It should neither be used for the development or implementation of an investment strategy nor be construed as an investment advice to any party or a promise on minimum returns and safeguard of capital. Invesco Asset Management (India) Pvt. Ltd./Invesco Mutual Fund is not guaranteeing or promising or forecasting any returns.

Key Facts

Type of Scheme

An open ended equity scheme investing in Pharma, Healthcare and allied sectors

Category of the Scheme: Sectoral Fund

Investment Objective

To generate long term capital appreciation by investing predominantly in equity and equity related securities of the companies in Pharmaceuticals, Healthcare and allied sectors.

There is no assurance that the investment objective of the Scheme will be achieved.

Asset Allocation

Under normal circumstances, the asset allocation of the scheme would be as follows:

Type of Instruments	Indicative Allocation (% of Net Assets)	
	Minimum	Maximum
Equity and Equity related instruments of companies in the Pharma, Healthcare and allied sectors	80	100
Other equity and equity related instruments	0	20
Money Market / Other Liquid Instruments*	0	20
Gold / Silver ETFs	0	20
Units issued by InvITs	0	10

*Other liquid instruments shall include cash, bank deposits with Scheduled Commercial Banks, Government Securities, Treasury bills, Repo on Government securities and any other instruments as specified by SEBI.

Plans*/Options: Regular Plan and Direct Plan

- Growth option
- Income Distribution cum capital withdrawal ('IDCW')
- IDCW Payout
- IDCW Reinvestment

(if IDCW payable under IDCW payout option is equal or less than ₹100/- then the IDCW would be compulsory reinvested in the respective plan/option of the scheme).

Minimum Application Amount (During NFO and ongoing basis)

Lumpsum: ₹1,000 and in multiples of ₹1 thereafter

For Systematic Investment Plan (SIP):

Frequency	Daily*	Weekly	Monthly	Quarterly
No. of Installments	60	12	12	4
Minimum Amount	₹100	₹100	₹100	₹300

And in multiples of ₹1 thereafter

Load Structure:

Exit Load®: For each purchase of units through Lumpsum / Switch-in / Systematic Investment Plan (SIP), Systematic Transfer Plan (STP) and IDCW Transfer Plan, exit load will be as follows:

- if units are redeemed/switched out on or before 3 months from the date of allotment: 0.50%
- if units are redeemed/switched-out after 3 months from the date of allotment: **Nil**
- Switch between plans under the scheme: **Nil**

Fund Manager: Mr. Aditya Khemani

Benchmark: BSE Healthcare TRI

*Available only through Digital Platforms. ^Direct Plan will have a lower expense ratio excluding distribution expenses, commission for distribution of Units etc.

®Exit Load charged, if any, will be credited back to the scheme, net of Goods & Services Tax.

Benchmark based on Total Return variant of respective Benchmark Index. TRI: Total Return Index.

 **Call 1800-209-0007**
invescomutualfund.com

Follow us on



Distributed by:

ARN Code:

EUIN Code:

M:

E:

Address:

Invesco Asset Management (India)

Invesco Asset Management (India) offers expertise across equity and fixed income investments, with a broad range of funds to suit your every investment need. Our aim is to provide best-in-class investment products across asset classes, regions and risk spectrum, with high standards of customer service.

Invesco Limited – One of the world's leading independent global investment management firms

- US\$2.2 trillion in assets under management around the globe
- Specialised investment teams managing investments across a wide range of asset classes and investment styles
- More than 7,400 employees worldwide
- On-the-ground presence in more than 20 countries, serving clients in more than 120 countries

Source: AUM of \$2,159.9 billion, client-related data, investment professional and employee data as of March 31, 2026. AUM includes all assets under advisement, distributed and overseen by Invesco.

Disclaimer: This document alone is not sufficient and shouldn't be used for the development or implementation of an investment strategy. It should not be construed as investment advice to any party. All figures, charts/graphs and data included in this document are as on date and are subject to change without notice. The data used in this document is obtained by Invesco Asset Management (India) Private Limited from the sources which it considers reliable. While utmost care has been exercised while preparing this document, Invesco Asset Management (India) Private Limited does not warrant the completeness or accuracy of the information and disclaims all liabilities, losses and damages arising out of the use of this information. The content of this document is intended solely for the use of the addressee. If you are not the addressee or the person responsible for delivering it to the addressee, any disclosure, copying, distribution or any action taken or omitted to be taken in reliance on it is prohibited and may be unlawful. The recipient(s) before acting on any information herein should make his/their own investigation and seek appropriate professional advice.

Mutual Fund investments are subject to market risks, read all scheme related documents carefully.